Comparison Chart BioLineRx Ltd.

Equities

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:35 2024-07-04 EDT			5-day change	1st Jan Change
15 ^ILa	+1.35%		-1.96%	-60.73%

05-30	BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	CI
05-28	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	BIOLINERX LTD.	Bio Therapeutic Drugs	+1.35%	-1.96%	-60.73%	-62.22%	-87.84%	48.71M